雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Fc Fusion Protein as a Novel Treatment for Myasthenia Gravis Akiyuki Uzawa 1 , Junji Yamashita 2 , Satoshi Kuwabara 1 1Department of Neurology, Graduate School of Medicine, Chiba University 2Research Laboratory, Nihon Pharmaceutical Co. Ltd Keyword: 重症筋無力症 , 融合蛋白 , 革新的治療 , B細胞 , 動物モデル , myasthenia gravis , fusion protein , novel treatment , B cell , animal model pp.525-530
Published Date 2019/5/1
DOI https://doi.org/10.11477/mf.1416201306
  • Abstract
  • Look Inside
  • Reference

Abstract

Myasthenia gravis (MG) is an inflammatory disorder caused by autoantibodies against the nicotinic acetylcholine receptor (AChR). New therapeutic options for MG are required because the conventional treatments cannot always achieve long-term remission in MG patients. We developed a fusion protein, AChR-Fc, as a novel therapeutic agent for patients with MG. It is composed of the extracellular domain of human AChR-α1 subunit and human IgG1. AChR-Fc exhibited dual activities: it neutralized anti-AChR antibodies and demonstrated an enhanced cytotoxicity against autoantibody-producing B cells. Therefore, AChR-Fc is a novel biomolecule that can be used in the treatment of patients with MG, and potentially overcomes the disorder.


Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有